# Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Canonical URL: https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-result-86ae0b14
Ticker: AKBA
Company: Akebia Therapeutics
Source: Akebia Therapeutics
Published: 2026-02-19 13:00 EST
## Summary

Akebia to Host Conference Call on February 26 at 8:00 a.m. EST February 19, 2026 08:00 ET | Source: Akebia Therapeutics, In...

## Article Body
Akebia to Host Conference Call on February 26 at 8:00 a.m. EST

February 19, 2026 08:00 ET | Source: Akebia Therapeutics, Inc.

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets.

Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link , and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/ . An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com .

About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com
## Recent Company News
- 2026-07-02 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc8c2359) — Source: Akebia Therapeutics
- 2026-06-30 12:00 EST — [U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA](https://biopharmsignal.com/news/AKBA/u-s-renal-care-and-akebia-announce-interim-analysis-of-voice-trial-demonstrated--7cc9c9bc) — Source: Akebia Therapeutics
- 2026-06-10 12:00 EST — [Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-strengthens-vafseo-vadadustat-patent-portfolio-17cb62c9) — Source: Akebia Therapeutics
- 2026-06-01 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eb3ccebf) — Source: Akebia Therapeutics
- 2026-05-28 12:00 EST — [Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-conferenc-a2e97fe3) — Source: Akebia Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)